Q&A with Brian Bolwell: Efficacy of Immunologic and Genomic Therapies

Video

Brian Bolwell, MD, Cleveland Clinic, discussed how all the information they're finding out about myeloid malignancies is very important, but also complex so making broad statements is challenging.

Brian Bolwell, MD, Cleveland Clinic, discussed how all the information they're finding out about myeloid malignancies is very important, but also complex so making broad statements is challenging.

Regarding progress, Bolwell stated, "As my role as director of the Cleveland Clinic, we're very concerned about healthcare economics and showing value, and ASH is at the forefront of trying to publicize the challenge of the ongoing challenge of the ongoing cost of targeted therapies."

Related Videos
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Veraprapas Kittipibul, MD | Credit: X.com
James Palmer, MD | Credit: Penn Medicine
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.